PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15238875

Does atazanavir cause lipodystrophy?

Brian G Gazzard·Graeme Moyle
View original source ↗Export metadata ↓

Abstract

Atazanavir is a once-a-day non-pepsidic inhibitor of HIV protease which is licensed for use in the UK and the USA. One of its major advantages is that it does not produce lipid abnormalities in patients who receive it. This feature has been widely interpreted as implying that in the future there will be no abnormalities associated with fat redistribution when the drug is administered. This article explores that view.

Explore related subjects

Antiretroviral Therapy, Highly ActiveAtazanavir SulfateHIV InfectionsHIV Protease InhibitorsHIV-Associated Lipodystrophy SyndromeHumansOligopeptidesPyridinesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Brian G Gazzard, Graeme Moyle. 2004. Does atazanavir cause lipodystrophy?. https://pubmed.ncbi.nlm.nih.gov/15238875/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Random changepoint modelling of HIV immunologic responses.

We propose a changepoint model for the analysis of longitudinal CD4 T-cell counts for HIV infected subjects following highly active antiretroviral treatment. The profile of CD4 counts for each subject follows a simple, 'broken stick' changepoint model, with random subject-specific parameters, including the changepoint. The model accounts for baseline covariates. The longitudinal CD4 records are censored at the time of the subject going off-study-treatment. This is a potentially informative drop-out mechanism, which we address by modelling it jointly with the CD4 count outcome. The drop-out model incorporates terms from the CD4 model, including the changepoint. The estimation is done in a Bayesian framework, with implementation via Markov chain Monte Carlo methods in the WinBUGS software. Model selection using DIC indicates that the data support the complex random changepoint and informative censoring model.

Antiretroviral Therapy, Highly Active↗
PubMed2007

Estimation and prediction with HIV-treatment interruption data.

We consider longitudinal clinical data for HIV patients undergoing treatment interruptions. We use a nonlinear dynamical mathematical model in attempts to fit individual patient data. A statistically-based censored data method is combined with inverse problem techniques to estimate dynamic parameters. The predictive capabilities of this approach are demonstrated by comparing simulations based on estimation of parameters using only half of the longitudinal observations to the full longitudinal data sets.

Antiretroviral Therapy, Highly Active↗